Medtronic, Alnylam and CHDI will develop a drug-device combo

11/3/2010 | Mass High Tech (Boston)

Alnylam Pharmaceuticals will work with Medtronic and CHDI Foundation to develop ALN-HTT, an RNAi-based drug for Huntington's disease that can be delivered by Medtronic's implantable infusion device. CHDI will fund as much as 50% of requirements necessary for seeking regulatory approval of the drug-device combination. Medtronic and Alnylam will have an equal share in the partnership in the U.S.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY